Proteomics approaches to understand linkage between Alzheimer's disease and type 2 diabetes mellitus

CNS and Neurological Disorders - Drug Targets

Volumn 13, Issue 2, 2014, Pages 213-225

  Mirza, Zeenat ^a   Ali, Ashraf ^a   Ghulam, Md ^a   Kamal, Mohammad A ^a   Abuzenadah, Adel M ^a   Choudhary, Adeel G ^a   Damanhouri, Ghazi A ^a   Sheikh, Ishfaq A ^a  

^a KING ABDULAZIZ UNIVERSITY   (Saudi Arabia)

Author keywords

Alzheimer's disease; Biomarker; Diabetes mellitus type 2; Proteomic linkage

Indexed keywords

3 NITROTYROSINE; 4 HYDROXYNONENAL; ACETYLCHOLINESTERASE; ACTIN; ADIPONECTIN; ALPHA 1 ANTITRYPSIN; APOLIPOPROTEIN A1; APOLIPOPROTEIN E; BIOLOGICAL MARKER; CARBONYL DERIVATIVE; CHOLINESTERASE; COMPLEMENT FACTOR H; FERRITIN; GALECTIN 7; GLUCAGON LIKE PEPTIDE 1; GLYCOGEN SYNTHASE KINASE 3; HEMOPEXIN; INSULIN; ISOPROSTANE DERIVATIVE; METFORMIN; PIOGLITAZONE; PLASMA PROTEIN; PREALBUMIN; PROTEOME; RHOA GUANINE NUCLEOTIDE BINDING PROTEIN; ROSIGLITAZONE; TRANSFERRIN;

ALZHEIMER DISEASE; DISEASE ASSOCIATION; DNA DAMAGE; HIPPOCAMPUS; HUMAN; INFLAMMATION; INSULIN SENSITIVITY; LIPID PEROXIDATION; MASS SPECTROMETRY; MILD COGNITIVE IMPAIRMENT; MOLECULAR PATHOLOGY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PHASE 2 CLINICAL TRIAL (TOPIC); PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; PROTEOMICS; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; TWO DIMENSIONAL GEL ELECTROPHORESIS; ANIMAL; DIABETES MELLITUS, TYPE 2; METABOLISM; PROCEDURES;

ALZHEIMER DISEASE; ANIMALS; BIOLOGICAL MARKERS; DIABETES MELLITUS, TYPE 2; HUMANS; PROTEOMICS;

EID: 84921911946     PISSN: 18715273     EISSN: 19963181     Source Type: Journal    
DOI: 10.2174/18715273113126660144     Document Type: Review

References (185)

1. About Alzheimer Disease. Bright Focus Foundation; 2012. www.ahaf.org/alzheimers
2. Wild S, Roglic G, Green A, Sicree R, King H. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care 2004; 27: 1047-53.
3. Nicolls MRD, Antonio JM, Hutton JC, et al. Proteomics as a tool for discovery: Proteins implicated in Alzheimer's disease are highly expressed in normal pancreatic islets. J Proteome Res 2003; 2: 199-205.
4. Grossman H. Does diabetes protect or provoke Alzheimer's disease? Insights into the pathobiology and future treatment of Alzheimer's disease. CNS Spectr 2003; 8(11): 815-23.
5. Götz J, Ittner LM, Lim Y. Common features between diabetes mellitus and Alzheimer's disease. Cell Mol Life Sci 2009; 66(8): 1321-5.
6. Farris W, Mansourian S, Chang Y, et al. Insulin-degrading enzyme regulates the levels of insulin, amyloid beta-protein, and the beta-amyloid precursor protein intra-cellular domain in vivo. Proc Natl Acad Sci USA 2003; 100: 4162-7.
7. Miller BC, Eckman EA, Sambamurti K, et al. Amyloid-beta peptide levels in brain are inversely correlated with insulysin activity levels in vivo. Proc Natl Acad Sci USA 2003; 100: 6221-6.
8. Farris W, Mansourian S, Leissring MA, et al. Partial loss-of-function mutations in insulin-degrading enzyme that induce diabetes also impair degradation of amyloid beta-protein. Am J Pathol 2004; 164: 1425-34.
9. Hayden MR, Tyagi SC. "A" is for Amylin and Amyloid in Type 2 Diabetes Mellitus; JOP. J Pancreas 2001; 2(4): 124-39.
10. Rivera EJ, Goldin A, Fulmer N, et al. Insulin and insulin-like growth factor expression and function deteriorate with progression of Alzheimer's disease: link to brain reductions in acetylcholine. J Alzheimers Dis 2005; 8: 247-68.
11. Steen E, Terry BM, Rivera EJ, et al. Impaired insulin and insulin-like growth factor expression and signaling mechanisms in Alzheimer's disease -is this type 3 diabetes? J Alzheimers Dis 2005; 7: 63-80.
12. Berndt J, Kloting N, Kralisch S, et al. Plasma visfatin concentrations and fat depot-specific mRNA expression in humans. Diabetes 2005; 54: 2911-6.
13. Considine RV, Sinha MK, Heiman ML, et al. Serum immunoreactiveleptin concentrations in normal-weight and obese humans. N Eng J Med 1996; 334: 292-5.
14. Hotta K, Funahashi T, Arita Y, et al. Plasma concentrations of a novel, adipose-specific protein, adiponectin, in type 2 diabetic patients. Arterioscler Thromb Vasc Biol 2000; 20: 1595-9.
15. Norata GD.; Ongari M, Garlaschelli K, et al. Plasma resistin levels correlate with determinants of the metabolic syndrome. Eur J Endocrinol 2007; 156: 279-84.
16. Vozarova B, Weyer C, Hanson K, et al. Circulating interleukin-6 in relation to adiposity, insulin action, and insulin secretion. Obes Res 2001; 9: 414-7.
17. Jiang M, Jia L, Jiang W, et al. Protein disregulation in red blood cell membranes of type 2 diabetic patients. Biochem Biophys Res Commun 2003: 309: 196-200.
18. Jiang M, Ding Y, Su Y, et al. Arginase-flotillin interaction brings arginase to red blood cell membrane. FEBS Lett 2006; 580: 6561-4.
19. Zhang R, Barker L, Pinchev D, et al. Mining biomarkers in human sera using proteomic tools. Proteomics 2004; 4: 244-56.
20. Heliovaara MK, Teppo AM, Karonen SL, et al. Plasma IL-6 concentration is inversely related to insulin sensitivity, and acute-phase proteins associate with glucose and lipid metabolism in healthy subjects. Diabetes Obes Metab 2005; 7: 729-36.
21. Festa A, D'Agostino Jr R, Tracy RP, Haffner SM. Elevated levels of acutephase proteins and plasminogen activator inhibitor-1 predict the development of type 2 diabetes: the insulin resistance atherosclerosis study. Diabetes 2002; 51: 1131-7.
22. Sundsten T, Zethelius B, Berne C, Bergsten P. Plasma proteome changes in type 2 diabetes mellitus subjects with low or high early insulin response. Clin Sci (Lond) 2008a; 114: 499-507.
23. Juntti-Berggren L, Refai E, Appelskog I, et al. Apolipoprotein CIII promotes Ca2+-dependent beta cell death in type 1 diabetes. Proc Natl Acad Sci USA 2004; 101: 10090-4.
24. Gervaise N, Garrigue MA, Lasfargues G, Lecomte P. Triglycerides, apo C3 and Lp B: C3 and cardiovascular risk in type II diabetes. Diabetologia 2000; 43: 703-8.
25. Kim SW, Hwang HJ, Kim HM, et al. Effect of fungal polysaccharides on the modulation of plasma proteins in streptozotocin-induced diabetic rats. Proteomics 2006; 6: 5291-302.
26. Itoh N, Hanafusa T, Miyagawa J, et al. Transthyretin (prealbumin) in the pancreas and sera of newly diagnosed type I (insulin-dependent) diabetic patients. J Clin Endocrinol Metab 1992; 74: 1372-7.
27. Myron Johnson A, Merlini G, Sheldon J, Ichihara K. Clinical indications for plasma protein assays: transthyretin (prealbumin) in inflammation and malnutrition. Clin Chem Lab Med 2007; 45: 419-26.
28. Pickup JC. Inflammation and activated innate immunity in the pathogenesis of type 2 diabetes. Diabetes Care 2004; 27: 813-23.
29. Sjoholm A, Nystrom T. Inflammation and the etiology of type 2 diabetes. Diabetes Metab Res Rev 2006; 22: 4-10.
30. Gabay C, Kushner I. Acute-phase proteins and other systemic responses to inflammation. N Engl J Med 1999; 340: 448-54.
31. Mehdi H, Nunn M, Steel DM, et al. Nucleotide sequence and expression of the human gene encoding apolipoprotein H (beta 2-glycoprotein I). Gene 1991; 108: 293-8.
32. Castaneda C, Bermudez OI, Tucker KL. Protein nutritional status and function are associated with type 2 diabetes in Hispanic elders. Am J Clin Nutr 2000; 72: 89-95.
33. Narita T, Hosoba M, Kakei M, Ito S. Increased urinary excretions of immunoglobulin g, ceruloplasmin, and transferrin predict development of microalbuminuria in patients with type 2 diabetes. Diabetes Care 2006; 29: 142-4.
34. Cho WC, Yip TT, Chung WS, et al. Differential expression of proteins in kidney, eye, aorta, and serum of diabetic and non-diabetic rats. J Cell Biochem 2006; 99: 256-68.
35. Pradhan AD, Manson JE, Rifai N, et al. C-reactive protein, interleukin 6: and risk of developing type 2 diabetes mellitus. JAMA 2001; 286: 327-34.
36. Schreiber G, Tsykin A, Aldred AR, et al. The acute phase response in the rodent. Ann NY Acad Sci 1989; 557: 61-85.
37. Tsuneki H, Ishizuka M, Terasawa M, et al. Effect of green tea on blood glucose levels and serum proteomic patterns in diabetic (db/db) mice and on glucose metabolism in healthy humans. BMC Pharmacol 2004; 4: 18.
38. Kiga C, Nakagawa T, Koizumi K, et al. Expression patterns of plasma proteins in spontaneously diabetic rats after oral administration of a Kampo medicine, Hachimi-jio-gan, using SELDI ProteinChip platform. Biol Pharm Bull 2005; 28: 1031-7.
39. Kolberg JA, Jorgensen T, Gerwien RW, et al. Development of a type 2 diabetes risk model from a panel of serum biomarkers from the Inter99cohort. Diabetes Care 2009; 32: 1207-12.
40. Salomaa V, Havulinna A, Saarela O, et al. Thirty-one novel biomarkers as predictors for clinically incident diabetes. PLoS One 2010; 5(4): e10100.
41. Wu H, Yu Z, Qi Q, et al. Joint analysis of multiple biomarkers for identifying type 2 diabetes in middle-aged and older Chinese: A crosssectional study. Br Med J 2011; 1: e000191.
42. Memisogullari R, Bakan E. Levels of ceruloplasmin, transferrin, and lipid peroxidation in the serum of patients with Type 2 diabetes mellitus. J Diabetes Compl 2004; 18: 193-7.
43. Sundsten T, Eberhardson M, Goransson M, Bergsten P. The use of proteomics in identifying differentially expressed serum proteins in humans with type 2 diabetes. Proteome Sci 2006; 4: 22.
44. Sundsten T, Ostenson CG, Bergsten P. Serum protein patterns in newly diagnosed type 2 diabetes mellitus -Influence of diabetic environment and family history of diabetes. Diabetes Metab Res Rev 2008a; 24: 148-54.
45. Riaz S, Alam SS, Akhtar MW. Proteomic identification of human serum biomarkers in diabetes mellitus type 2. J Pharm Biomed Anal 2010a; 51: 1103-7.
46. Li RX, Chen HB, Tu K, et al. Localized-statistical quantification of human serum proteome associated with type 2 diabetes. PLoS One 2008; 3: e3224.
47. Hampel H, Mitchell A, Blennow K, et al. Core biological marker candidates of Alzheimer's disease-perspectives for diagnosis, prediction of outcome and reflection of biological activity. J Neural Transm 2004; 111: 247-72.
48. Jabbour W, Pouplard-Barthelaix A, Houlgatte R, et al. Abnormal expression of actin in lymphocytes of Alzheimer's disease and Down's syndrome patients. J Neuroimmunol 1992; 38: 199-208.
49. Mattila KM, Frey H. Two-dimensional analysis of qualitative and quantitative changes in blood cell proteins in Alzheimer's disease: search for extraneuronal markers. Appl Theor Electrophor 1995; 4: 189-96.
50. Alafuzoff I, Adolfsson R, Bucht G, et al. Isoelectric focusing and two-dimensional gel electrophoresis in plasma and cerebrospinal fluid from patients with dementia. Eur Neurol 1986; 25: 285-9.
51. Ai KZ, Vermuyten K, De Deyn PP, et al. A serum protein involved in aging? Mol Chem Neuropathol 1989; 11: 131-41.
52. Ueno I, Sakai T, Yamaoka M, et al. Analysis of blood plasma proteins in patients with Alzheimer's disease by two-dimensional electrophoresis, sequence homology and immunodetection. Electrophoresis 2000; 21: 1832-45.
53. Zhang R, Barker L, Pinchev D, et al. Mining biomarkers in human sera using proteomic tools. Proteomics 2004; 4: 244-56.
54. Righetti PG, Castagna A, Antonucci F, et al. Proteome analysis in the clinical chemistry laboratory: myth or reality? Clin Chim Acta 2005; 357: 123-39.
55. Ryberg H, Bowser R. Protein biomarkers for amyotrophic lateral sclerosis. Expert Rev Proteomics 2008; 5: 249-62.
56. Goldknopf IL. Blood-based proteomics for personalized medicine: examples from neurodegenerative disease. Expert Rev Proteomics 2008; 5: 1-8.
57. Hye A, Lynham S, Thambisetty M, et al. Proteome-based plasma biomarkers for Alzheimer's disease. Brain 2006; 129: 3042-50.
58. Thambisetty M, Hye A, Foy C, et al. Proteome-based identification of plasma proteins associated with hippocampal metabolism in early Alzheimer's disease. J Neurol 2008; 255: 1712-20.
59. Liu HC, Hu CJ, Chang JG, et al. Proteomic identification of lower apolipoprotein A-I in Alzheimer's disease. Dement Geriatr Cogn Disord 2006; 21: 155-61.
60. Roher AE, Maarouf CL, Sue LI, et al. Proteomics-derived cerebrospinal fluid markers of autopsy-confirmed Alzheimer's disease. Biomarkers 2009; 14(7): 493-501.
61. Song F, Poljak A, Smythe GA, et al. Plasma biomarkers for mild cognitive impairment and Alzheimer's disease. Brain Res Rev 2009; 61: 69-80.
62. Desrosiers RR, Bertrand Y, Nguyen QT, et al. Expression of melanotransferrin isoforms in human serum: relevance to Alzheimer's disease. Biochem J 2003; 374: 463-71.
63. Yu HL, Chertkow HM, Bergman H, et al. Aberrant profiles of native and oxidized glycoproteins in Alzheimer plasma. Proteomics 2003; 3: 2240-8.
64. Choi J, Malakowsky CA, Talent JM, et al. Identification of oxidized plasma proteins in Alzheimer's disease. Biochem Biophys Res Commun 2002; 293: 1566-70.
65. Mhyre TR, Loy R, Tariot PN, et al. Proteomic analysis of peripheral leukocytes in Alzheimer's disease patients treated with divalproex sodium. Neurobiol Aging 2008; 29: 1631-43.
66. Poljak A, Sachdev P, Smythe GA. Causes and diagnosis of Alzheimer's disease: a proteomics approach. Proteomics 2006; 81-112.
67. Blasko I, Jellinger K, Kemmler G, et al. Conversion from cognitive health to mild cognitive impairment and Alzheimer's disease: prediction by plasma amyloid beta 42: medial temporal lobe atrophy and homocysteine. Neurobiol Aging 2008; 29: 1-11.
68. Graff-Radford NR, Crook JE, Lucas J, et al. Association of low plasma Abeta42/Abeta40 ratios with increased imminent risk for mild cognitive impairment and Alzheimer disease. Arch Neurol 2007; 64: 354-62.
69. Hansson O, Zetterberg H, Buchhave P, et al. Prediction of Alzheimer's disease using the CSF Abeta42/Abeta40 ratio in patients with mild cognitive impairment. Dement Geriatr Cogn Disord 2007; 23: 316-20.
70. Locascio JJ, Fukumoto H, Yap L, et al. Plasma amyloid beta-protein and C-reactive protein in relation to the rate of progression of Alzheimer disease. Arc Neurol 2008; 65: 776-85.
71. Mayeux R, Honig LS, Tang MX, et al. Plasma A+AFs-beta+AF0-40 and A+AFs-beta+AF0-42 and Alzheimer's disease: relation to age, mortality, and risk. Neurology 2003; 61: 1185-90.
72. Pomara N, Willoughby LM, Sidtis JJ, Mehta PD. Selective reductions in plasma A beta 1-42 in healthy elderly subjects during longitudinal follow-up: a preliminary report. Am J Geriatr Psychiatry 2005; 13: 914-7.
73. Van Oijen M, Hofman A, Soares HD, Koudstaal PJ, Breteler MM. Plasma Abeta(1-40) and Abeta(1-42) and the risk of dementia: a prospective case-cohort study. Lancet Neurol 2006; 5: 655-60.
74. DeMattos RB, Bales KR, Cummins DJ, Paul SM, Holtzman DM. Brain to plasma amyloid-beta efflux: a measure of brain amyloid burden in a mouse model of Alzheimer's disease. Science 2002; 295: 2264-7.
75. Schenk D, Barbour R, Dunn W, et al. Immunization with amyloid β attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature 1999; 400: 173-7.
76. Bard F, Cannon C, Barbour R, et al. Peripherally administered antibodies against amyloid beta peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease. Nat Med 2000; 6: 916-9.
77. Nicoll JA, Wilkinson D, Holmesm C, et al. Neuropathology of human Alzheimer disease after immunization with amyloid-β peptide: a case report. Nat Med 2003; 9: 448-52.
78. Hock C, Konietzko U, Papassotiropoulos A, et al. Generation of antibodies specific for β amyloid by vaccination of patients with Alzheimer disease. Nat Med 2002; 8: 1270-5.
79. Hock C, Konietzko U, Streffer JR, et al. Antibodies against β amyloid slow cognitive decline in Alzheimer's disease. Neuron 2003; 38: 547-54.
80. Orgogozo JM, Gilman S, Dartigues JF, et al. Subacute meningoencephalitis in a subset of patients with AD after Aβ42 immunization. Neurology 2003; 61: 46-54.
81. Solfrizzi V, D'Introno A, Colacicco AM, et al. Circulating biomarkers of cognitive decline and dementia. Clin Chim Acta 2006; 364: 91-112.
82. Pratico D. Peripheral biomarkers of oxidative damage in Alzheimer's disease: the road ahead. Neurobiol Aging 2005; 26: 581-3.
83. Greco A, Minghetti L, Levi G. Isoprostanes, novel markers of oxidative injury, help understanding the pathogenesis of neurodegenerative diseases. Neurochem Res 2000; 25: 1357-64.
84. Pratico D, Lee VMY, Trojanowski JQ, Rokach J, Fitzgerald GA. Increased F2-isoprostanes in Alzheimer's disease: evidence for enhanced lipid peroxidation in vivo. FASEB J 1998; 12: 1777-83.
85. Montine TJ, Beal MF, Cudkowicz ME, et al. Increased CSF F2-isoprostane concentration in probable AD. Neurology; 1999: 52: 562-5.
86. Pratico D, Clark CM, Lee VM, et al. Increased 8: 12-iso-iPF2alpha-VI in Alzheimer's disease: correlation of a noninvasive index of lipid peroxidation with disease severity. Ann Neurol 2000; 48: 809-12.
87. Pratico D, Clark CM, Liun F, et al. Increase of brain oxidative stress in mild cognitive impairment: a possible predictor of Alzheimer disease. Arch Neurol 2002; 59: 972-6.
88. Montine TJ, Quinn JF, Milatovic D, et al. Peripheral F2-isoprostanes and F4-neuroprostanes are not increased in Alzheimer's disease. Ann Neurol 2002; 52: 175-9.
89. Weiner HL, Selkoe DJ. Inflammation and therapeutic vaccination in CNS diseases. Nature 2002; 420: 879-84.
90. Teunissen CE, de Vente J, Steinbusch HW, De Bruijn C. Biochemical markers related to Alzheimer's dementia in serum and cerebrospinal fluid. Neurobiol Aging 2002; 23: 485-508.
91. Licastro F, Pedrini S, Caputo L, et al. Increased plasma levels of interleukin-1: interleukin-6 and α -1-antichymotrypsin in patients with Alzheimer's disease: peripheral inflammation or signals from the brain? J Neuroimmunol 2000; 103: 97-102.
92. Singh VK, Guthikonda P. Circulating cytokines in Alzheimer's disease. J Psychiatr Res 1997; 31: 657-60.
93. Tarkowski E, Blennow K, Wallin A, Tarkowski A. Intracerebral production of tumor necrosis factor-α a local neuroprotective agent, in Alzheimer disease and vascular dementia. J Clin Immunol 1999; 19: 223-30.
94. Maes M, DeVos N, Wauters A, et al. Inflammatory markers in younger vs elderly normal volunteers and in patients with Alzheimer's disease. J Psychiatr Res 1999; 33: 397-405.
95. Kalman J, Juhasz A, Laird G, et al. Serum interleukin-6 levels correlate with the severity of dementia in Down syndrome and in Alzheimer's disease. Acta Neurol Scand 1997; 96: 236-40.
96. Bonaccorso S, Lin A, Song C, et al. Serotonin-immune interactions in elderly volunteers and in patients with Alzheimer's disease (DAT): lower plasma tryptophan availability to the brain in the elderly and increased serum interleukin-6 in DAT. Aging 1998; 10: 316-23.
97. Blum-Degen D, Muller T, Kuhn W, et al. Interleukin-1β and interleukin-6 are elevated in the cerebrospinal fluid of Alzheimer's and de novo Parkinson's disease patients. Neurosci Lett 1995; 202: 17-20.
98. Angelis P, Scharf S, Mander A, Vajda F, Christophidis N. Serum interleukin-6 and interleukin-6 soluble receptor in Alzheimer's disease. Neurosci Lett 1998; 244: 106-8.
99. Chao CC, Ala TA, Hu S, et al. Serum cytokine levels in patients with Alzheimer's disease. Clin Diagn Lab Immunol 1994; 1: 433-6.
100. Van Duijn CM, Hofman A, Nagelkerken L. Serum levels of interleukin-6 are not elevated in patients with Alzheimer's disease. Neurosci Lett 1990; 108: 350-4.
101. Dik MG, Jonker C, Hack CE, et al. Serum inflammatory proteins and cognitive decline in older persons. Neurology 2005; 64: 1371-7.
102. Schmidt R, Schmidt H, Curb JD, et al. Early inflammation and dementia: a 25-year follow-up of the Honolulu-Asia Aging Study. Ann Neurol 2002; 52: 168-74.
103. Yaffe K, Lindquist K, Penninx BW, et al. Inflammatory markers and cognition in well-functioning African-American and white elders. Neurology 2003; 61: 76-80.
104. Engelhart MJ, Geerlings MI, Meijer J, et al. Inflammatory proteins in plasma and the risk of dementia: the rotterdam study. Arch Neurol 2004; 61: 668-72.
105. Birkenhager WH, Forette F, et al. Blood pressure, cognitive functions, and prevention of dementias in older patients with hypertension. Arch Intern Med 2001; 161: 152-6.
106. Notkola IL, Sulkava R, Pekkanen J, et al. Serum total cholesterol, apolipoprotein E epsilon 4 allele, and Alzheimer's disease. Neuroepidemiology 1998; 17: 14-20.
107. Hofman A, Ott A, Breteler MM, et al. Atherosclerosis, apolipoprotein E, and prevalence of dementia and Alzheimer's disease in the Rotterdam Study. Lancet 1997; 349: 151-4.
108. Kivipelto M, Helkala EL, Laakso MP, et al. Midlife vascular risk factors and Alzheimer's disease in later life: longitudinal, population-based study. Br Med J 2001; 322: 1447-51.
109. Evans RM, Emsley CL, Gao S, et al. Serum cholesterol, APOE genotype, and the risk of Alzheimer's disease: a population-based study of African Americans. Neurology 2000; 54: 240-2.
110. Yaffe K, Barrett-Connor E, Lin F, Grady D. Serum lipoprotein levels, statin use, and cognitive function in older women. Arch Neurol 2002; 59: 378-84.
111. Jarvik GP, Wijsman EM, Kukull WA, et al. Interactions of apolipoprotein E genotype, total cholesterol level, age, and sex in prediction of Alzheimer's disease: a case-control study. Neurology 1999; 45: 1092-6.
112. Sachdev PS. Homocysteine and brain atrophy. Prog Neuropsychopharmacol Biol Psychiatry 2005; 29: 1152-61.
113. Boushey CJ, Beresford SA, Omenn GS, Motulsky AGA. Quantitative assessment of plasma homocysteine as a risk factor for vascular disease; Probable benefits of increasing folic acid intakes. JAMA 1995; 274: 1049-57.
114. Seshadri S, Beiser A, Selhub J, et al. Plasma homocysteine as a risk factor for dementia and Alzheimer's disease. N Engl J Med 2002; 346: 476-83.
115. Dietschy JM, Turley SD. Cholesterol metabolism in the brain. Curr Opin Lipidol 2001; 12: 105-12.
116. Papassotiropoulos A, Lutjohann D, Bagli M, et al. 24S-hydroxycholesterol in cerebrospinal fluid is elevated in early stages of dementia. J Psychiatr Res 2002; 36: 27-32.
117. Schonknecht P, Lutjohann D, Pantel J, et al. Cerebrospinal fluid 24S-hydroxycholesterol is increased in patients with Alzheimer's disease compared to healthy controls. Neurosci Lett 2002; 324: 83-5.
118. Lutjohann D, Papassotiropoulos A, Bjorkhem I, et al. Plasma 24S-hydroxycholesterol (cerebrosterol) is increased in Alzheimer and vascular demented patients. J Lipid Res 2000; 41: 195-8.
119. Saunders A, Strittmater W, Schmechel D, et al. Association of apolipoprotein E allele&4 with late-onset familial and sporadic Alzheimer's disease. Neurology 1993; 43: 1467-72.
120. Gomez-Isla T, West HL, Rebeck GW, et al. Clinical and pathological correlates of apolipoprotein E & 4 in Alzheimer's disease. Ann Neurol 1996; 39: 62-70.
121. Mann DM, Iwatsubo T, Pickering-Brown SM, et al. Preferential deposition of amyloid beta protein (Aβ) in the form Aβ40 in Alzheimer's disease is associated with a gene dosage effect of the apolipoprotein E &4 allele. Neurosci Lett 1997; 221: 81-4.
122. Corder EH, Saunders AM, Risch NJ, et al. Protective effect of apolipoprotein E type 2 allele for late onset Alzheimer disease. Nat Genet 1994; 7: 180-4.
123. German DC, Gurnani P, Nandi A, et al. Serum biomarkers for Alzheimer's disease: proteomic discovery. Biomed Pharmacother 2007; 61: 383-9.
124. Ganguli M, Dodge HH, Shen C, DeKosky ST. Mild cognitive impairment, amnestic type: an epidemiologic study. Neurology 2004; 63: 115-21.
125. Chen M, Inestrosa NC, Ross GS, Fernandez HL. Platelets are the primary source of amyloid beta-peptide in human blood. Biochem Biophys Res Commun 1995; 213: 96-103.
126. Ferri CP, Prince M, Brayne C, et al. Global prevalence of dementia: a Delphi consensus study. Lancet 2005; 366: 2112-7.
127. Farlow MR, He Y, Tekin S, et al. Impact of APOE in mild cognitive impairment. Neurology 2004; 63: 1898-901.
128. Janson J, Laedtke T, Parisi JE, et al. Increased risk of type 2 diabetes in Alzheimer disease. Diabetes 2004; 53: 474-81.
129. Kutty KM, Huang SN, Kean KT. Pseudocholinesterase in obesity: hypercaloric diet induced changes in experimental obese mice. Experimentia 1981; 37: 1141-2.
130. Kutty KM, Payne RH. Serum pseudocholinesterase and verylow density lipoprotein metabolism. J Clin Lab Anal 1994; 8; 247-50.
131. Greig NH, Utsuki T, Ingram DK, et al. Selective butyrylcholinesterase inhibition elevated brain acetylcholine, augments learning and lowers Alzheimer beta-amyloid peptide in rodent. Proc Natl Acad Sci USA 2005; 102: 17213-8.
132. Lehmann DJ, Johnston C, Smith AD. Synergy between the genes for butyrylcholinesterase K variant and apolipoprotein E4 in late-onset confirmed Alzheimer's disease. Hum Molec Genet 1997; 6: 1933-6.
133. Sridhar GR, Nirmala G, Allam AR, et al. Serum butyrylcholinesterase in type 2 diabetes mellitus: a biochemical and bioinformatics approach. Lipid Health Dis 2005; 4: 18.
134. Mattila KM, Rinne Jom Roytta M, Laippala P, et al. Dipeptidyl carboxypeptidase 1 (Dcp1) and butyrylcholinesterase (BCHE) gene interactions with the apolipoprotein E epsison4 allele as risk factors in Alzheimer's disease and in Parkinson's disease with coexisting Alzheimer pathology. J Med Genet 2000; 37: 766-70.
135. Raygani AV, Zahrai M, Soltanzadeh A, et al. Analysis of association between butyrylcholinesterase K variant and apolipoprotein E genotypes in Alzheimer's disease. Neurosci Lett 2004; 371: 142-6.
136. Sridhar GR, Nirmala G. Inborn errors in lipid metabolism. In Lipid disorders Edited by: Tripathy BB, Das S. Assocsiation of Physicians of India, API College of Physicians; 2002; pp. 59-80.
137. Suarez D, Diaz N, Camps JF, Field MJ. A computational study of deacylation mechanism of human butyrylcholinesterase. Biochemistry 2006; 45: 7529-43.
138. Rustemeijer C, Schouten JA, Voerman HJ, et al. Is pseudocholinesterase activity related to markers of triacylglycerol synthesis in type II diabetes mellitus? Clin Sci 2001; 101: 29-35.
139. Blesa R, Bullock R, He Y, et al. Effect of butyrylcholinesterase genotype on the response to rivastigmine or donepezil in younger patients with Alzheimer's disease. Pharmacogenet Genom 2006; 16: 771-4.
140. Birks J. Cholinesterase inhibitors for Alzheimer's disease. Cochrane Data Syst Rev 2006; CD005593.
141. Diamant S, Podoly E, Friedler A, et al. Butyrylcholinesterase attenuates amyloid fibril formation in vitro. Proc Natl Acad Sci USA 2006; 103: 8628-33.
142. Johansen AEM, Nielsen D, Andersen G, et al. Large-scale studies of the functional K variant of the butyrylcholinesterase gene in relation to Type 2 diabetes and insulin secretion. Diabetologia 2004; 47: 1437-41.
143. Vionnet N, Hani EH, Dupont S, et al. Genomewise search for type 2 diabetes susceptibility genes in French Whites: evidence for a novel susceptibility locus for early-onset diabetes on chromosome 3q27-qter and independent replication of a type 2 diabetes locus on chromosome 1q21-q24. Am J Hum Genet 2000; 67: 1470-80.
144. Sun MK, Alkon DL. Links between Alzheimer's disease and diabetes. Drugs Today 2006; 42: 481-9.
145. Grossman H. Does diabetes protect or provoke Alzheimer's disease? Insights into the pathobiology and future treatment of Alzheimer's disease. CNS Spectr 2003; 8: 815-23.
146. Randell EW, Mathews MS, Zhang H, Seraj JS, Sun G. Relationship between serum butyrylcholinesterase and the metabolic syndrome. Clin Biochem 2005; 38: 799-805.
147. Craft S, Reger MA, Baker LD. Insulin resistance in Alzheimer's disease - a novel therapeutic target. Alzheimer's disease and related disorders Annual 5. Taylor and Francis, London 2006; pp. 111-33.
148. Gao C, Holscher C, Liu Y, Li L. GSK3: a key target for the development of novel treatments for type 2 diabetes mellitus and Alzheimer disease. Rev Neurosci 2011; 23(1): 1-11.
149. Eldar-Finkelman H. Glycogen synthase kinase 3: an emerging therapeutic target. Trends Mol Med 2002; 8(3): 126-32.
150. Jope RS, Johnson GV. The glamour and gloom of glycogen synthase kinase-3. Trends Biochem Sci 2004; 29(2): 95-102.
151. Jope RS, Yuskaitis CJ, Beurel E. Glycogen synthase kinase-3 (GSK3): inflammation, diseases, and therapeutics. Neurochem Res 2007; 32(4-5): 577-95.
152. Kramer T, Schmidt B, Lo Monte F. Small-Molecule Inhibitors of GSK-3: Structural Insights and Their Application to Alzheimer's Disease Models. Int J Alzheimers Dis 2012; 2012: 381029.
153. Hu S, Begum AN, Jones MR, et al. GSK3 inhibitors show benefits in an Alzheimer's disease (AD) model of neurodegeneration but adverse effects in control animals. Neurobiol Dis 2009; 33(2): 193-206.
154. Rayasam GV, Tulasi VK, Sodhi R, Davis JA, Ray A. Glycogen synthase kinase 3: more than a namesake. Br J Pharmacol 2009; 156(6): 885-98.
155. Mossello E, Ballini E, Boncinelli M, et al. Glucagon-Like Peptide-1: Diabetes, and Cognitive Decline: Possible Pathophysiological Links and Therapeutic Opportunitie. Exp Dia Res 2011; 2011: 281674.
156. Nauck M, Stockmann F, Ebert R, Creutzfeldt W. Reduced incretin effect in Type 2 (non-insulin-dependent) diabetes. Diabetologia 1986; 29(1): 46-52.
157. Mannucci E, Ognibene A, Cremasco F, et al. Glucagon-like peptide (GLP)-1 and leptin concentrations in obese patients with Type 2 diabetes mellitus. Diabetic Med 2000; 17(10): 713-9.
158. Vilsbøll T, Krarup T Deacon CF, Madsbad S, Holst JJ. Reduced postprandial concentrations of intact biologically active glucagon-like peptide 1 in type 2 diabetic patients. Diabetes 2001; 50(3): 609-13.
159. Rask E, Olsson T, Söderberg S, et al. Impaired incretin response after a mixed meal is associated with insulin resistance in nondiabetic men. Diab Care 2001; 24(9): 1640-5.
160. Rask E, Olsson T, Söderberg S, et al. Insulin secretion and incretin hormones after oral glucose in non-obese subjects with impaired glucose tolerance. Metabolism 2004; 53(5): 624-31.
161. Li Y, Duffy KB, Ottinger MA, et al. GLP-1 receptor stimulation reduces amyloid-β peptide accumulation and cytotoxicity in cellular and animal models of Alzheimer's disease. J Alzheimers Dis 2010; 19(4): 1205-19.
162. McClean PL, Gault VA, Harriott P, Hölscher C. Glucagon-like peptide-1 analogues enhance synaptic plasticity in the brain: a link between diabetes and Alzheimer's disease. Eur J Pharmacol 2010; 630(1-3): 158-62.
163. Hamilton A, Patterson S, Porter D, Gault VA, Hölscher C. Novel GLP-1 mimetics developed to treat type 2 diabetes promote progenitor cell proliferation in the brain. J Neuro Res 2011; 89(4): 481-9.
164. David DC, Ittner LM, Gehrig P, et al. Beta-amyloid treatment of two complementary P301L tau-expressing Alzheimer's disease models reveals similar deregulated cellular processes. Proteomics 2006; 6: 6566-77.
165. Kawahara M, Kuroda Y, Arispe N, Rojas E. Alzheimer's-amyloid, human islet amylin and prion protein fragment evoke intracellular free calcium elevations by a common mechanism in a hypothalamic GnRH neuronal cell line. J Biol Chem 2000; 274: 14077-83.
166. Kourie JI, Henry CL. Ion channel formation and membrane-linked pathologies of misfolded hydrophobic proteins: the role of dangerous unchaperoned molecules. Clin Exp Pharmacol Physiol 2002; 29: 741-53.
167. Lim YA, Ittner LM, Lim YL, Gotz J. Human but not rat amylin shares neurotoxic propertieswith Abeta42 in long-term hippocampal and cortical cultures. FEBS Lett 2008; 582: 2188-94.
168. Lorenzo A, Razzaboni B, Weir GC, Yankner BA. Pancreatic islet cell toxicity of amylin associated with type-2 diabetes mellitus. Nature 1994; 368(6473): 756-60.
169. Lim YA, Rhein V, Baysang G, et al. Abeta and human amylin share a common toxicity pathway via mitochondrial dysfunction. Proteomics 2010; 10(8): 1621-33.
170. Mosconi L, Nacmias B, Sorbi S, et al. Brain metabolic decreases related to the dose of the ApoE e4 allele in Alzheimer's disease. J Neurol Neurosurg Psychiatry 2004; 75: 370-6.
171. Mosconi L, Herholz K, Prohovnik I, et al. Metabolic interaction between ApoE genotype and onset age in Alzheimer's disease: implications for brain reserve. J Neurol Neurosurg Psychiatry 2005; 76: 15-23.
172. Irie F, Fitzpatrick AL, Lopez OL, et al. Enhanced risk for Alzheimer disease in persons with type 2 diabetes and APOE epsilon4: the Cardiovascular Health Study Cognition Study. Arch Neurol 2008; 65: 89-93.
173. Leissring MA, Farris W, Chang AY, et al. Enhanced proteolysis of beta-amyloid in APP transgenic mice prevents plaque formation, secondary pathology, and premature death. Neuron 2003; 40: 1087-93.
174. Qiu WQ, Folstein MF. Insulin, insulin-degrading enzyme and amyloid-beta peptide in Alzheimer's disease: review and hypothesis. Neurobiol Aging 2006; 27: 190-8.
175. Miller BW, Willett KC, Desilets AR. Rosiglitazone and pioglitazone for the treatment of Alzheimer's disease. Ann Pharmacother 2011; 45(11): 1416-24.
176. Kitamura Y, Shimohama S, Koike H, et al. Increased expression of cyclooxygenases and peroxisome proliferator-activated receptor-gamma in Alzheimer's disease brains. Biochem Biophys Res Commun 1999; 254: 582-6.
177. Berger J, Moller DE. The mechanisms of action of PPARs. Annu Rev Med 2002; 53: 409-35.
178. Geldmacher DS, Fritsch T, McClendon MJ, Landreth G. A Randomized Pilot Clinical Trial of the Safety of Pioglitazone in Treatment of Patients with Alzheimer Disease. Arch Neurol 2011; 68(1): 45-50.
179. Sato T, Hanyu H, Hirao K, et al. Efficacy of PPAR-γ agonist pioglitazone in mild Alzheimer disease. Neurobiol Aging 2011; 32(9): 1626-33.
180. Akter K, Lanza EA, Martin SA, et al. Diabetes mellitus and Alzheimer's disease: shared pathology and treatment? Br J Clin Pharmacol 2011; 71(3): 365-76.
181. Columbia University, Institute for the Study of Aging, National Institute on Aging. Metformin in amnestic mild cognitive impairment (MCI). Available at http://clinicaltrialsgov/ct2/show/NCT00620191; (last verified and updated 12 April 2011; last accessed 14 January 2013).
182. Arnold SE. Effect of Insulin Sensitizer Metformin on Alzheimer's Disease Biomarkers. Bright focus foundation; Clarksburg, MD, USA 2012. Available from: http://www.brightfocus.org/research/grants/migrated/effect-of-insulin-sensitizer.html
183. Reger MA, Watson GS, Frey WH 2nd, et al. Effects of intranasal insulin on cognition in memory-impaired older adults: modulation by APOE genotype. Neurobiol Aging 2006; 27: 451-8.
184. Reger MA, Watson GS, Green PS, et al. Intranasal insulin improves cognition and modulates beta-amyloid in early AD. Neurology 2008; 70: 440-8.
185. Gotz J, Schild A, Hoerndli F, Pennanen L. Amyloid-induced neurofibrillary tangle formation in Alzheimer's disease: Insight from transgenic mouse and tissue-culture models. Int J Dev Neurosci 2004; 22: 453-65.